Doris Augustin
A5027450608- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- BRCA gene mutations in cancer
- Esophageal Cancer Research and Treatment
- Neutropenia and Cancer Infections
- Protease and Inhibitor Mechanisms
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Risks and Factors
Deggendorf Institute of Technology
2011-2023
Technische Universität Ilmenau
2019
University of Duisburg-Essen
2019
University of Kassel
2019
Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR)
2019
Technical University of Darmstadt
2019
TU Dortmund University
2019
Ludwig-Maximilians-Universität München
2004-2018
Breast Center
2010-2018
Bethesda Hospital
2018
The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET) alone. Here, we report five-year data evaluating prognostic value RS, Ki-67, and other traditional clinicopathological parameters. A central tumour bank was prospectively established within PlanB. Following an amendment, hormone receptor (HR)+ , RS ≤ 11 were...
Purpose Human epidermal growth factor receptor 2 (HER2)–positive/hormone (HR)–positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little known about the efficacy of combination endocrine therapy (ET) trastuzumab or potent antibody-cytotoxic, anti-HER2 compound emtansine (T-DM1) without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted...
Background Invasive lobular breast cancer (BC) is the second most common BC subtype. Prognostic parameters (tumor classification, lymph node status, histologic grade, Oncotype DX recurrence score [RS], progesterone receptor and Ki67 index) were retrospectively studied in a large, prospective clinical trial encompassing 2585 patients who had hormone receptor‐positive early (the West German Study Group PlanB trial). Methods BCs centrally reviewed classified as (n = 353; 14%) or nonlobular...
The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment metastatic breast cancer (MBC).This randomized, phase III, open-label, multicenter enrolled MBC patients who were ineligible endocrine or trastuzumab therapy. Cumulative adjuvant anthracyclines 360 mg/m2 equivalent allowed. Left ventricular ejection fraction >50 % was required. Patients received PLD 50 every 28 days 1250 twice daily 14 21...
The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14–16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based available evidence and ensure that all patients worldwide receive adequate access new therapies. This year, conference focused developments study results with hormone receptor-positive/HER2-negative as well precision medicine. As previous years, patient advocates from around world were...
Today, more than 70% of patients with primary node-negative breast cancer are cured by local therapy alone. Many receive overtreatment adjuvant chemotherapy due to inadequate risk assessment. So far, few clinical trials have prospectively evaluated tumor biology based prognostic factors. Risk assessment a biological algorithm including invasion factors urokinase-type plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) will assess up 35-55% as low-risk thus avoid chemotherapy. In...
Abstract Background: In HER2+ early breast cancer (eBC) pCR rates after standard neoadjuvant chemo- + anti-HER2 therapy differ according to hormone-receptor (HR) status. Molecular analysis reveals HER2+/HR+ BC as a distinct entity within BC. The ADAPT phase II trial aims identify responders endocrine therapy. Methods: completed recruitment in January 2015 (n=376). Patients (pts.) were randomized 12 weeks of therapy: A:T-DM1 (3.6 mg/kg q3w) vs. B:T-DM1 with (ET) (pre-: tamoxifen;...
JCO
506 Background: Evidence suggests differential efficacy of standard neoadjuvant chemo- + targeted therapy in HER2+ early breast cancer (eBC) according to hormone-receptor (HR) status. ADAPT HER2+/H...
Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone receptor-positive phase II trial (NCT01779206) demonstrated pathological complete response (pCR) rates of ~40% following de-escalated with 12 weeks neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy. In this exploratory analysis, we evaluated potential predictors to effects PIK3CA mutations and immune (CD8 PD-L1) apoptotic markers...
Abstract Background: Both the Recurrence Score® (RS) multi-gene assay and invasion factors uPA/PAI-1 are recommended by guidelines (ASCO, AGO) for decision support regarding adjuvant chemotherapy (cht) in patients with early breast cancer (BC). In EC-DOC trial, we previously suggested central grade 3 high Ki-67 levels as independent predictive markers enhanced benefit of taxane-based cht intermediate risk BC. Here, present final WSG-Plan B trial correlation analysis these assessment tools....
Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and tolerability of epirubicin (E)/cyclophosphamide (C) followed by docetaxel (Doc) with a dose-dense 5-fluorouracil (F)+E+ C regimen. The ADEBAR was randomised phase III trial for women primary invasive cancer ⩾4 metastatic axillary lymph nodes (n=1364). Treatment consisted four 21-day cycles E plus C, Doc (EC-Doc), or six 28-day F (FEC120)....
Data from meta-analyses have shown taxane-containing therapies to be superior anthracycline-based treatments for high-risk breast cancer.The ADEBAR trial was a multicenter phase III in which patients with lymph node-positive cancer were prospectively randomized either sequential anthracycline-taxane or FEC120 therapy. Patients received 4× epirubicin (90 mg/m(2)) and cyclophosphamide (600 every 3 weeks (q3w), followed by docetaxel (100 q3w (EC-Doc arm), 6× (60 5-fluorouracil (500 on days 1 8...